From signal to significance: characterizing anthracycline-related hypercoagulable adverse events via pharmacovigilance, animal models, and clinical observation
{{output}}
Background: Anthracyclines are widely used antineoplastic agents with well-recognized cardiotoxicity; however, reports of hypercoagulable adverse events (HC-AEs) remain scattered and incompletely described. A systematic character... ...